The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

The Jonathan Jaques Children's Cancer Institute at Miller Children's & Women's Hospital was involved in a pivotal Children's Oncology Group study that has reshaped the standard of care for children ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- What Does The C5 Complement Inhibitors Market Landscape Look Like? The market for C5 complement inhibitors, critical ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The recent FDA approval in IgG4-related disease and the strong clinical evidence in myasthenia gravis, underscore Amgen's ongoing leadership in developing innovative treatments targeting CD19 ...

Amgen said the FDA has accepted its application seeking approval of Uplinza as a treatment for myasthenia gravis, with a decision due by December 14.

Amgen shares slid 4.5% after the biotech revealed ... which is in development for a muscle weakening disease called myasthenia gravis, didn’t appear as effective as already approved therapies ...

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the drug would ...

Myasthenia gravis is a rare neuromuscular disorder caused ... and rozanolixizumab (Rystiggo). Drugmaker Amgen expects to complete an FDA submission for inebilizumab in gMG in the first half ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis. Amgen’s anti-CD19 antibody Uplizna ...